MENU

BIOR Stock Biora Therapeutics (BIOR, $4.3) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 18, 2024

A.I.dvisor
at Tickeron.com
10/19/24
Loading...
BIOR - Biora Therapeutics Inc
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $4.3
Daily change: -$1.238 (-22.35%)
Daily volume: 296.4K
Industry: Biotechnology
This is a Bearish indicator signaling BIOR's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 36 similar cases where BIOR's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

BIOR saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for BIOR moved out of overbought territory on October 18, 2024. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In of the 41 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 18, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BIOR as a result. In of 64 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BIOR turned negative on October 18, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BIOR entered a downward trend on October 11, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for BIOR's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOR advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

BIOR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.594). P/E Ratio (0.000) is within average values for comparable stocks, (111.595). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.971). BIOR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (25.974) is also within normal values, averaging (224.025).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BIOR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
BIOR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in the provision of molecular and specialized diagnostic tests to clinicians

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
4330 La Jolla Village Drive
Phone
+1 833 727-2841
Employees
58
Web
https://www.bioratherapeutics.com